TipRanks tools are all you need to make data-driven investment decisions. Conduct comprehensive stock research, find new investment ideas, analyze your portfolio, and follow the best-performing Wall Street experts, with ease.
The Rigel stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.
Rigel Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. It discovers and develops novel, targeted drugs in the therapeutic areas of immunology, oncology and immune oncology. The firm focuses on intracellular signalling pathways and related targets that are critical to disease mechanisms. Its products include Tavalisse, Fostamatinib and R835. The company was founded by Donald G. Payan, James M. Gower, Thomas A. Raffin, Garry P. Nolan and Ronald B. Garren on June 14, 1996 and is headquartered in South San Francisco, CA.
What was Rigel’s price range in the past 12 months?
Rigel lowest stock price was $2.21 and its highest was $5.50 in the past 12 months.
What is Rigel’s market cap?
Rigel’s market cap is $638.98M.
What is Rigel’s price target?
The average price target for Rigel is $11.00. This is based on 1 Wall Streets Analysts 12-month price targets, issued in the past 3 months. The highest analyst price target is $11.00 ,the lowest forecast is $11.00. The average price target represents 194.12% Increase from the current price of $3.74.
What do analysts say about Rigel?
Rigel’s analyst rating consensus is a ‘Moderate Buy. This is based on the ratings of 1 Wall Streets Analysts.
When is Rigel’s upcoming earnings report date?
Rigel’s upcoming earnings report date is Nov 09, 2021 which is next month.
How were Rigel’s earnings last quarter?
Rigel released its earnings results on Aug 03, 2021. The company reported -$0.081 earnings per share for the quarter, beating the consensus estimate of -$0.109 by $0.028.
Is Rigel overvalued?
According to Wall Street analysts Rigel’s price is currently Undervalued.
Does Rigel pay dividends?
Rigel does not currently pay dividends.
What is Rigel’s EPS estimate?
Rigel’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Rigel have?
Rigel has 170,850,000 shares outstanding.
What happened to Rigel’s price movement after its last earnings report?
Rigel reported an EPS of -$0.081 in its last earnings report, beating expectations of -$0.109. Following the earnings report the stock price went down -7.214%.
Which hedge fund is a major shareholder of Rigel?
Among the largest hedge funds holding Rigel’s share is Driehaus Capital Management LLC. It holds Rigel’s shares valued at 1M.